Promises and pitfalls of electronic health record analysis

Diabetologia

Volumn 61, Issue 6, 2018, Pages 1241-1248

  Farmer, Ruth ^a   Mathur, Rohini ^a   Bhaskaran, Krishnan ^a   Eastwood, Sophie V ^b   Chaturvedi, Nish ^b   Smeeth, Liam ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes; Electronic health records; Epidemiology; Observational studies; Primary care; Review; Secondary care

Indexed keywords

CLINICAL PRACTICE; CLINICAL RESEARCH; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE EXACERBATION; ELECTRONIC HEALTH RECORD; HUMAN; INCIDENCE; INFORMATION PROCESSING; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SELECTION BIAS; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION; ACCESS TO INFORMATION; HEALTH CARE QUALITY; OBSERVATIONAL STUDY; PRIMARY HEALTH CARE; PROCEDURES;

ACCESS TO INFORMATION; DATA COLLECTION; DIABETES MELLITUS; DISEASE PROGRESSION; ELECTRONIC HEALTH RECORDS; HUMANS; INCIDENCE; OBSERVATIONAL STUDIES AS TOPIC; PREVALENCE; PRIMARY HEALTH CARE; QUALITY OF HEALTH CARE;

EID: 85038114310     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4518-6     Document Type: Review

References (47)

1. Edwards L, Rooshenas L, Isaacs T (2016) Inclusion of ethnic minorities in telehealth trials for type 2 diabetes: protocol for a systematic review examining prevalence and language issues. JMIR Res Protoc 5:e43
2. Hussain-Gambles M, Atkin K, Leese B (2004) Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community 12:382–388
3. Zhang T, Tsang W, Wijeysundera HC, Ko DT (2013) Reporting and representation of ethnic minorities in cardiovascular trials: a systematic review. Am Heart J 166:52–57
4. Coloma PM, Schuemie MJ, Trifirò G et al (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20:1–11
5. Chamberlain JJ, Herman WH, Leal S et al (2017) Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association standards of medical care in diabetes. Ann Intern Med 166:572–578
6. Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541–549
7. Brauer R, Douglas I, Garcia Rodriguez LA et al (2016) Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. Pharmacoepidemiol Drug Saf 25(Suppl 1):29–38
8. Bhaskaran K, Douglas I, Forbes H, dos Santos-Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384:755–765
9. Herrett E, Thomas SL, Schoonen M, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4–14
10. Wilchesky M, Tamblyn RM, Huang A (2004) Validation of diagnostic codes within medical services claims. J Clin Epidemiol 57:131–141
11. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490
12. Herrett E, Gallagher AM, Bhaskaran K et al (2015) Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 44:827–836
13. Shah AD, Langenberg C, Rapsomaniki E et al (2015) Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol 3:105–113
14. Mathur R, Bhaskaran K, Edwards E et al (2017) Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the Clinical Practice Research Datalink 2004–2014. BMJ Open 7:e014444
15. Holden SH, Barnett AH, Peters JR et al (2013) The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010. Diabetes Obes Metab 15:844–852
16. Poppe KK, Doughty RN, Wells S et al (2017) Developing and validating a cardiovascular risk score for patients in the community with prior cardiovascular disease. Heart 103:891–892
17. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT (2012) 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 344:e356
18. Hong JL, McNeill AM, He J, Chen Y, Brodovicz KG (2016) Identification of impaired fasting glucose, healthcare utilization and progression to diabetes in the UK using the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf 25:1375–1386
19. Sancho-Mestre C, Vivas-Consuelo D, Alvis-Estrada L, Romero M, Usó-Talamantes R, Caballer-Tarazona V (2016) Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data. BMC Health Serv Res 16:394
20. Solomon DH, Massarotti GR, Lium J, Canning C, Schneeweiss S (2011) Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305:2525–2531
21. van Staa TP, Patel D, Gallagher AM, de Bruin ML (2012) Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55:654–665
22. Herrett E, Shah AD, Boggon R et al (2013) Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 346:f2350
23. Bradley CJ, Penberthy L, Devers KJ, Holden DJ (2010) Health services research and data linkages: issues, methods, and directions for the future. Health Serv Res 45:1468–1488
24. Kildemoes HW, Sørensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39(7 Suppl):38–41
25. Green A, Sortsø C, Jensen PB, Emneus M (2015) Validation of the Danish National Diabetes Register. Clin Epidemiol 7:5–15
26. Christensen H, Nielsen JS, Sørensen KM, Melbye M, Brandslund I (2012) New national Biobank of The Danish Center for Strategic Research on Type 2 Diabetes (DD2). Clin Epidemiol 4:37–42
27. Sudlow C, Gallacher J, Allen N et al (2015) UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12:e1001779
28. Patorno E, Patrick AR, Garry EM et al (2014) Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia 57:2237–2250
29. Eastwood SV (2016) Algorithms for the capture and adjudication of prevalent and incident diabetes in UK biobank. PLoS One 11:e0162388
30. Lewis JD, Bilker WB, Weinstein RB, Strom BL (2005) The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 14:443–451
31. Prentice RL, Langer R, Stefanick ML et al (2005) Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 162:404–414
32. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920
33. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511–513
34. Levesque LE, Hanley JA, Kezouth A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087
35. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673
36. Farmer RE, Ford D, Forbes HJ et al (2017) Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation. Int J Epidemiol 46:745
37. Robins JM, Hernán MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11:550–560
38. Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JA (2013) Methods for dealing with time-dependent confounding. Stat Med 32:1584–1618
39. White IR, Carlin JB (2010) Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med 29:2920–2931
40. Bhaskaran K, Smeeth L (2014) What is the difference between missing completely at random and missing at random? Int J Epidemiol 43:1336–1339
41. Carpenter J, Kenward M (2012) Multiple imputation and its application. Wiley, Chichester
42. Carpenter JR, Kenward MG, White IR (2007) Sensitivity analysis after multiple imputation under missing at random: a weighting approach. Stat Methods Med Res 16:259–275
43. Sterne JAC, White IR, Carlin JB et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393
44. Kypri K, Wilson A, Attia J, Sheeran P, Miller P, McCambridge J (2016) Social desirability bias in the reporting of alcohol consumption: a randomized trial. J Stud Alcohol Drugs 77:526–531
45. Lipsitch M, Tchetgen Tchetgen E, Cohen T (2010) Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21:383–388
46. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35:337–344
47. Benchimol EI, Smeeth L, Guttmann A et al (2015) The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med 12:e1001885